Two Sigma Investments LP Sells 206,342 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

Two Sigma Investments LP trimmed its position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 34.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 390,800 shares of the company's stock after selling 206,342 shares during the period. Two Sigma Investments LP owned approximately 0.78% of Immunocore worth $11,529,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in shares of Immunocore by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 35,492 shares of the company's stock valued at $1,047,000 after purchasing an additional 420 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after acquiring an additional 960 shares in the last quarter. NEOS Investment Management LLC raised its holdings in Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after acquiring an additional 1,102 shares in the last quarter. Assetmark Inc. raised its holdings in Immunocore by 5.3% during the fourth quarter. Assetmark Inc. now owns 32,171 shares of the company's stock worth $949,000 after acquiring an additional 1,616 shares in the last quarter. Finally, Virtus ETF Advisers LLC raised its holdings in Immunocore by 39.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock worth $340,000 after acquiring an additional 3,238 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Bros. Advisors Lp Baker bought 807,338 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were bought at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the transaction, the director now owns 2,144,060 shares of the company's stock, valued at $63,721,463.20. This trade represents a 60.40% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.40% of the stock is owned by company insiders.

Immunocore Stock Performance

NASDAQ IMCR traded up $1.33 during trading on Thursday, reaching $32.82. 293,377 shares of the company's stock were exchanged, compared to its average volume of 390,148. The business has a 50 day moving average price of $29.12 and a 200-day moving average price of $29.98. The stock has a market capitalization of $1.64 billion, a P/E ratio of -34.64 and a beta of 0.75. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore Holdings plc has a fifty-two week low of $23.15 and a fifty-two week high of $49.05.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.45. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The company had revenue of $125.13 million for the quarter, compared to the consensus estimate of $108.82 million. During the same quarter in the prior year, the business earned ($0.49) earnings per share. The firm's revenue for the quarter was up 33.6% on a year-over-year basis. Sell-side analysts forecast that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on IMCR shares. Deutsche Bank Aktiengesellschaft started coverage on Immunocore in a report on Tuesday. They set a "buy" rating and a $65.00 target price on the stock. Oppenheimer upped their target price on Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. JPMorgan Chase & Co. dropped their target price on Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a report on Monday, April 14th. Morgan Stanley reiterated an "equal weight" rating and set a $35.00 target price on shares of Immunocore in a report on Friday, March 7th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $71.00 target price on shares of Immunocore in a report on Thursday, April 10th. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, Immunocore has a consensus rating of "Moderate Buy" and a consensus price target of $58.89.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.